Outcome of childhood acute lymphoblastic leukemia in Jordan

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 385-391

  Halalsheh, Hadeel ^a   Abuirmeileh, Najyah ^a   Rihani, Rawad ^a   Bazzeh, Faiha ^a   Zaru, Luna ^a   Madanat, Faris ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

Children; Jordan; Leukemia; Survival

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CYTOGENETICS; DRUG DOSE INCREASE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE;

ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; JORDAN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79960153379     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23065     Document Type: Article

References (48)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
2. Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000; 12: 3-12.
3. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adoles cents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813-819.
4. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
5. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood 2004; 104: 2690-2696.
6. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2009; 27: 5175-5181.
7. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
8. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
9. Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003; 21: 184-188.
10. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310-3322.
11. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
12. Mitchell C, Payne J, Wade R, et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: Results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 2009; 146: 424-436.
13. Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005; 130: 489-500.
14. Mehta PA, Davies SM. Allogeneic transplantation for childhood ALL. Bone Marrow Transplant 2008; 41: 133-139.
15. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
16. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635-642.
17. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004; 291: 2471-2475.
18. Gao YJ, Lu FJ, Wang HS. Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: The experience of a single children's hospital in China. J Pediatr Hematol Oncol 2006; 28: 798-802.
19. Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 397-405.
20. Liu Y, Chen J, Tang J, et al. Cost of childhood acute lymphoblastic leukemia care in Shanghai, China. Pediatr Blood Cancer 2009; 53: 557-562.
21. Al-Nasser A, El-Solh H, De Vol E, et al. Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: A single-institution experience. Ann Saudi Med 2008; 28: 251-259.
22. Karimi M, Yarmohammadi H, Sabri MR. An analysis of prognostic factors and the five-year survival rate in childhood acute lymphoblastic leukemia. Med Sci Monit 2002; 8: CR792-CR796.
23. Ribeiro RC, Steliarova-Foucher E, Magrath I, et al. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: A descriptive study. Lancet Oncol 2008; 9: 721-729.
24. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
25. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
26. Pui CH, Relling MV, Sandlund JT, et al. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004; 83: S124-S126.
27. Health Mo. Cancer incidence in Jordan. Jordan cancer registry booklet, 2007. pp. 67-68.
28. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: Update on prognostic factors. Curr Opin Pediatr 2009; 21: 1-8.
29. Advani S, Pai S, Venzon D, et al. Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen. Ann Oncol 1999; 10: 167-176.
30. Campbell M, Salgado C, Quintana J, et al. Improved outcome for acute lymphoblastic leukemia in children of a developing country: Results of the Chilean National Trial PINDA 87. Med Pediatr Oncol 1999; 33: 88-94.
31. Magrath I, Shanta V, Advani S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. Eur J Cancer 2005; 41: 1570-1583.
32. Rajajee S, Desikulu MV, Pushpa V. Survival of childhood acute lymphoblastic leukemia: Experience in Chennai. J Trop Pediatr 1999; 45: 367-370.
33. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer 1991; 3: 1-7.
34. Mesquita DR, Cordoba JC, Magalhaes IQ, et al. Molecular and chromosomal mutations among children with B-lineage lymphoblastic leukemia in Brazil's Federal District. Genet Mol Res 2009; 8: 345-353.
35. Lilleyman J. Simple deliverable therapy needed for childhood leukaemia. Lancet 2003; 362: 676-677.
36. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet 2003; 362: 706-708.
37. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999; 93: 2817-2823.
38. Cheok MH, Pottier N, Kager L, et al. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 39-51.
39. Hakooz N, Arafat T, Payne D, et al. Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population. Eur J Clin Pharmacol 2010; 66: 999-1003.
40. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735-746.
41. Prucker C, Attarbaschi A, Peters C, et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: A population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia 2009; 23: 1264-1269.
42. Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010; 28: 648-654.
43. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168-5174.
44. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
45. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 1094-1104.
46. Simonds EF, Davis KL, Lacayo NJ. Speeding the flow toward personalized therapy in childhood acute leukemia. Pediatr Blood Cancer 2009; 53: 525-526.
47. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
48. Galderisi F, Stork L, Li J, et al. Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia. Pediatr Blood Cancer 2009; 53: 543-550.